

CRISPR Therapy

Subjects: **Biology**

Contributor: Ignacio García-Tuñón

In the last two decades, the therapeutic landscape of several tumors have changed profoundly with the introduction of drugs against proteins encoded by oncogenes. Oncogenes play an essential role in human cancer and when their encoded proteins are inhibited by specific drugs, the tumoral process can be reverted or stopped. An example of this is the case of the chronic myeloid leukemia, in which all the pathological features can be attributed by a single oncogene. Most patients with this disease now have a normal life expectancy thanks to a rationally designed inhibitor. However, the drug only blocks the protein, the oncogene continues unaffected and treatment discontinuation is only an option for a small subset of patients. With the advent of genome-editing nucleases and, especially, the CRISPR/Cas9 system, the possibilities to destroy oncogenes now is feasible. A novel therapeutic tool has been developed with unimaginable limits in cancer treatment. Recent studies support that CRISPR/Cas9 system could be a definitive therapeutic option in chronic myeloid leukemia. This work reviews the biology of chronic myeloid leukemia, the emergence of the CRISPR system, and its ability as a specific tool for this disease.

CML

CRISPR/Cas9

BCR/ABL1

genome editing

1. Clinical Features of Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative disease with an incidence of 1–2 cases per 100,000 each year, accounting for 15% of all new cases of leukemia [1]. The frequency is higher among adults, in whom the mean age of incidence is about 55 years, and indeed, rarely arises during childhood. It may affect both sexes, but is slightly more common in males, with a ratio of 2.2 men to 1.4 women per 100,000 affected [1][2]. The most common clinical symptoms of CML include fatigue, anemia, splenomegaly, abdominal pain, and recurrent infections. However, a large proportion of asymptomatic patients are diagnosed after an unrelated medical examination [1]. Three clinical phases of its pathological evolution are recognized. At first, CML disease is characterized by a myeloid hyperplasia in an indolent chronic phase (CP). At this point, leukemic stem cells (LSCs) respond to growth factors, but myeloproliferative differentiation pathways acquire an advantage because they are the main cause of the massive myeloid expansion characteristic of CML [3]. In this initial phase, myeloid progenitors and mature cells accumulate in the blood and extramedullary tissues. Without effective therapy, CML progresses through a period of increasing instability known as the acceleration phase (AP), ending in an acute leukemic-like disease known as the blast crisis phase (BP). The definitions of AP and BP are largely dependent on the proportion of blasts in the blood and bone marrow. AP and BP are characterized by a maturation arrest in the myeloid or lymphoid lineage, and newly accumulated genetic and epigenetic aberrations occur in LSCs [4]. The final BP stage can result in a lymphoblastic (25%), myeloblastic (50%), or biphenotypic/undifferentiated acute leukemic phenotype (25%), which indicates a stem origin for CML disease [5], as shown in [Figure 1](#). Finally, bone marrow failure due to a lack of cell

differentiation, and a massive infiltration by immature blasts, causes patient mortality from infection, thrombosis, or anemia [6].




Figure 1. Chronic myeloid leukemia clinical phases. **(A)** Normal hematopoiesis characterized by the existence of hematopoietic stem cells with a controlled self-renewal and multipotency ability, resulting in balanced hematopoiesis between myeloid and lymphoid lineages. **(B)** In the chronic phase the myeloproliferative differentiation pathway acquires an advantage, and a massive myeloid expansion is produced. **(C)** Blast crisis is characterized by a maturation arrest in the myeloid or lymphoid lineage. Newly accumulated genetic and epigenetic aberrations appear in leukemic stem cells (LSCs) and blast cells go out from bone marrow to peripheral blood.

Diagnosis is based on detecting the hallmark of CML, the presence of the chromosome 22 abnormality known as Philadelphia (Ph), named after the US city in which it was first observed. It is the result of the reciprocal translocation between chromosomes 9 and 22-t(9;22) [7]. Conventional cytogenetics, fluorescence in situ hybridization (FISH), and reverse transcription PCR (RT-PCR) are the techniques commonly used to confirm a diagnosis of CML and to evaluate the response to therapy.

Before successful treatments became available, the median survival of CML patients after diagnosis was approximately 3–5 years [8][9]. The therapeutic landscape of CML changed profoundly with the introduction of tyrosine kinase inhibitor (TKI) drugs [8][10][11], and most patients with CP-CML now have a normal life expectancy. However, treatment discontinuation is only an option for a small subset of patients [12].

2. Molecular Biology of Chronic Myeloid Leukemia

Nowell and Hungerf, in 1960, first described the Ph chromosome, a small chromosome present in the bone marrow cells of CML patients [7]. It was the first time that a chromosomal abnormality had been linked to a particular

neoplasia [13]. Subsequent investigations confirmed that the generation of the Ph chromosome was due to the t(9;22) (q34;q11) translocation. The next breakthrough in our understanding of CML occurred in the 1980s, when it was demonstrated that this rearrangement gave rise to a fusion gene [14]. In this translocation, the analogue of the *v-ABL* protooncogene from chromosome 9 is moved to the breakpoint cluster region of the *BCR* gene on ch22. The location of the breakpoints between the two loci is variable [15]. Commonly, the breakpoint at the *ABL* locus occurs in a DNA region spanning more than 200 kb housing exon 2. At the *BCR* locus, the breakpoints occur in the major breakpoint cluster region (M-bcr), which spans a 3 kb region that includes exons 13 and 14 of *BCR*. All the rearrangements involving both breakpoint regions give rise to a 210 kDa protein, the most common chimeric transcript in CML [16]. However, in a minority of CML cases, the *BCR* breakpoint is located near exon 2, termed the minor breakpoint cluster region (m-bcr). In these cases, the resulting mRNA gives rise to a 190 kDa protein [15]. Finally, another infrequent breakpoint cluster region (μ -bcr) exists, downstream of *BCR* exon 19, which generates a 230 kDa protein when it is translocated to the *ABL1* locus [17], as shown in [Figure 2](#).




Figure 2. Structure of the *BCR/ABL1* oncogene. (A) Schematic representation of the t(9;22) (q34;q11) translocation triggering the Philadelphia chromosome. (B) Breakpoint locations between *BCR* and *ABL1* genes. Different fusion protein combinations yield different outcomes.

Since the *BCR/ABL1* fusion was described, the efforts of the scientific community have focused on elucidating its molecular roles in CML pathology. Several studies have shown the aberrant and constitutive tyrosine kinase activity of the *BCR/ABL1* oncoprotein, highlighting this activity as being responsible for the transformation of the hematopoietic stem cell [18][19][20][21]. The fusion of the two genes constitutively activates the tyrosine kinase domain of *ABL1*, which contains three SRC homology domains (SH1–SH3). The SH1 domain enables the tyrosine kinase function, whereas the SH2 and SH3 domains mediate interactions with other proteins [22]. The SH3 domain

is critical to the regulation of *ABL1* kinase activity, thereby presenting a target for clinical therapy. It is known that the fusion between the 5' end of *BCR* and the SH3 domain of *ABL1* abrogates the physiological suppression of the kinase [23]. Meanwhile, *BCR* has an important coiled-coil (CC) domain that will allow *BCR/ABL1* dimerization and subsequent trans-autophosphorylation, thus increasing the molecular signal [24], as shown in [Figure 3](#). The phosphorylation of the Y-177 tyrosine residue domain SH2 of *ABL* allows the high-affinity binding of the growth factor receptor-bound protein 2 (GRB2) as well as the scaffolding protein Gab2, activating the Ras pathway [25]. This aberrant kinase signaling activates many target proteins, such as the PI3K, AKT, JNK, and SRC family kinases, as well as transcription factors such as STATs, nuclear factor- κ B, and MYC [26][27][28].




Figure 3. *BCR/ABL* protein domains. Protein regions located in the *BCR* (A) and *ABL* (B) proteins, and those maintained in the fusion (C). The figure highlights the coiled-coil (CC) domain of *BCR*, which allows the dimerization of the oncoprotein, and the three SRC domains of *ABL1*, including the tyrosine kinase domain (SH1) and the regulatory domains (SH2 and SH3).

The constitutively active signaling causes cell reprogramming and expansion of the LSC clone. As a result, *BCR/ABL1*-positive hematopoietic stem cells exhibit uncontrolled proliferation [29], lack of response to apoptotic signals [30], alterations in cell adhesion [31], impaired differentiation [32], and independence of growth factors [33]. As a consequence, a myeloid differentiation bias is commonly observed in the chronic phase of CML.

3. Conventional Therapies for Chronic Myeloid Leukemia

The history of CML treatment can be considered one of the great milestones of modern cancer medicine. From its discovery until the 1980s, the standard treatment for CML consisted of conventional chemotherapy. Arsenic was the first treatment to be administered in the 19th century, but was superseded by alkylating drugs such as busulfan and hydroxyurea in the 1960s [34][35]. Unfortunately, they did not delay the onset of disease progression and facilitated only a modest improvement in survival. The introduction of interferon- α in the 1970s induced complete cytogenetic remission in 10–15% of patients, and increased median survival to 6 years [36]. However, interferon- α

treatment has serious side-effects, and treatment had to be discontinued in most patients, causing them to relapse. In this context, allogenic stem cell transplantation (SCT) was the only therapeutic option that could provide increased long-term survival, and so it became the first-line treatment in the 1990s for patients in the chronic phase [37][38][39]. Even today, this therapeutic option is the only one with the potential to definitively cure CML patients in this phase. The SCT procedure involves bone marrow ablation (by chemotherapy or radiotherapy) followed by the infusion of normal allogenic stem cells. However, it is only available to a small number of patients who have an HLA-matched donor, and is associated with a significant transplant-related mortality rate [39]. Nowadays, SCT is used solely as a last-resort salvage option.

As mentioned above, CML is a type of cancer in which all the pathological features can be attributed to a single genetic event, in this case the *BCR/ABL1* fusion. Knowing that the tyrosine kinase activity of *BCR/ABL1* is essential for the malignant transformation of cells, the search for compounds that inhibit this activity became imperative. During the 1990s, various tyrosine kinase inhibitors (TKIs) were tested to evaluate their therapeutic potential in CML [40][41]. The mechanism of action of these compounds is based on competition with adenosine triphosphate (ATP) or the protein substrate of the kinase, whereby *BCR/ABL1* activity is inhibited at the protein level. Finally, in the 2000s, the Novartis compound ST1571 (later known as imatinib mesylate), which showed surprising results by selectively inhibiting *BCR/ABL1* at micromolar concentrations, was approved as therapy for CML [42][43]. The arrival of TKIs marked a watershed in the treatment of CML and they remain the frontline therapy for CML. Thanks to TKIs, CP-CML patients, who, before 2001, had a survival rate of 20% at 8 years, now have a rate of 87%, and a life expectancy like those of healthy people of the same age [10][11][17]. Despite the success achieved with TKI-based treatments, there are still obstacles to overcome. The main concern is that TKI drugs do not tackle the etiological cause of CML and the oncogenic event remains uncorrected/unedited. The existence of residual *BCR/ABL*-positive cells, which remain “oncogenic-quiescent”, has been demonstrated, indicating that TKIs do not completely eliminate the LSCs [12]. TKIs efficiently silence the oncogenic activity of *BCR/ABL* while the drug is present, but the remaining LSCs can lead to relapse after TKI therapy ceases, as shown in [Figure 4](#).




Figure 4. Conventional therapies vs. gene therapy for chronic myeloid leukemia (CML). Tyrosine-kinase inhibitor (TKI)-based conventional therapies are effective at silencing *BCR/ABL1* in leukemic stem cells (LSCs). Treatment cessation can lead to relapse because of the existence of residual *BCR/ABL1*-positive cells. The appearance of TKI-resistant LSCs during treatment can lead to a relapse of the disease. However, anti-*BCR/ABL1* gene therapy would eliminate the oncogene at the genome level. Corrected LSCs would be able to repopulate the bone marrow niche and thereby enable normal hematopoiesis.

In this scenario, lifelong oral medication is necessary, and treatment discontinuation is only an option in those patients who were able to achieve and maintain strong molecular responses. Lifelong administration facilitates adverse effects in many patients and a significant percentage of them eventually become resistant to TKI treatment [44]. The identification of various forms of resistance has led to the development of second- and third-generation TKIs that are effective against kinase-specific mutations in these patients [45]. Taking this therapeutic scenario into account, it is still necessary to seek new and definitive alternative therapies. Currently, any coding sequence can be abolished by CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 nucleases [46][47][48] or zinc finger nuclease [49], which means there is an opportunity of a definitive cure available to TKI-resistant CML patients. Thus, CRISPR/Cas9 system could be a definitive therapeutic option.

References

1. Quintás-Cardama, A.; Cortes, J. Chronic Myeloid Leukemia: Diagnosis and Treatment. In Mayo Clinic Proceedings; Elsevier: Amsterdam, The Netherlands, 2006; Volume 81, pp. 973–988.

2. Mendizabal, A.M.; Garcia-Gonzalez, P.; Levine, P.H. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. *Cancer Epidemiol.* 2013, 37, 247–254.
3. Petzer, A.; Eaves, C.; Lansdorp, P.; Ponchio, L.; Barnett, M.; Eaves, A. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. *Blood* 1996, 88, 2162–2171.
4. Melo, J.V.; Barnes, D.J. Chronic Myeloid Leukemia: Biology of Advanced Phase. In *Myeloproliferative Disorders*; Springer: Berlin/Heidelberg, Germany, 2007; pp. 37–58.
5. Kantarjian, H.M.; Keating, M.J.; Talpaz, M.; Walters, R.S.; Smith, T.L.; Cork, A.; McCredie, K.B.; Freireich, E.J. Chronic myelogenous leukemia in blast crisis. *Am. J. Med.* 1987, 83, 445–454.
6. Ilaria, R.L. Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues. *Hematol. Am. Soc. Hematol. Educ. Program* 2005, 2005, 188–194.
7. Nowell, P. A minute chromosome in human chronic granulocytic leukemia. *Science* 1960, 132, 1497–1499.
8. Kantarjian, H.; O'Brien, S.; Jabbour, E.; Garcia-Manero, G.; Quintas-Cardama, A.; Shan, J.; Rios, M.B.; Ravandi, F.; Faderl, S.; Kadia, T.; et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. *Blood* 2012, 119, 1981–1987.
9. Chereda, B.; Melo, J.V. Natural course and biology of CML. *Ann. Hematol.* 2015, 94 (Suppl. 2), S107–S121.
10. Bower, H.; Björkholm, M.; Dickman, P.W.; Höglund, M.; Lambert, P.C.; Andersson, T.M.-L. Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. *J. Clin. Oncol.* 2016, 34, 2851–2857.
11. Deininger, M.; O'Brien, S.G.; Guilhot, F.; Goldman, D.J.M.; Hochhaus, A.; Hughes, T.P.; Radich, J.P.; Hatfield, A.K.; Mone, M.; Filian, J.; et al. International Randomized Study of Interferon Vs ST1571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. *Blood* 2009, 114, 1126.
12. Graham, S.M.; Jørgensen, H.G.; Allan, E.; Pearson, C.; Alcorn, M.J.; Richmond, L.; Holyoake, T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to ST1571 in vitro. *Blood* 2002, 99, 319–325.
13. Rowley, J.D. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining. *Nat. Cell Biol.* 1973, 243, 290–293.

14. Ben-Neriah, Y.; Daley, G.Q.; Mes-Masson, A.M.; Witte, O.N.; Baltimore, D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. *Science* 1986, 233, 212–214.
15. Score, J.; Calasanz, M.J.; Ottman, O.; Pane, F.; Yeh, R.F.; A Sobrinho-Simões, M.; Kreil, S.; Ward, D.; Hidalgo-Curtis, C.; Melo, J.V.; et al. Analysis of genomic breakpoints in p190 and p210 BCR–ABL indicate distinct mechanisms of formation. *Leukemia* 2010, 24, 1742–1750.
16. Groffen, J.; Stephenson, J.R.; Heisterkamp, N.; De Klein, A.; Bartram, C.R.; Grosveld, G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. *Cell* 1984, 36, 93–99.
17. Verstovsek, S.; Lin, H.; Kantarjian, H.; Saglio, G.; De Micheli, D.; Pane, F.; Garcia-Manero, G.; Intrieri, M.; Rotoli, B.; Salvatore, F.; et al. Neutrophilic-chronic myeloid leukemia: Low levels of p230 BCR/ABL mRNA and undetectable p230 BCR/ABL protein may predict an indolent course. *Cancer* 2002, 94, 2416–2425.
18. Lugo, T.G.; Pendergast, A.M.; Muller, A.J.; Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. *Science* 1990, 247, 1079–1082.
19. Kabarowski, J.H.; Witte, O.N. Consequences of BCR–ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia. *Stem Cells* 2000, 18, 399–408.
20. Zhou, H.; Xu, R. Leukemia stem cells: The root of chronic myeloid leukemia. *Protein Cell* 2015, 6, 403–412.
21. Janossy, G.; Roberts, M.; Greaves, M. Target Cell in Chronic Myeloid Leukæmia and Its Relationship to Acute Lymphoid Leukæmia. *Lancet* 1976, 308, 1058–1061.
22. Cohen, G.B.; Ren, R.; Baltimore, D. Modular binding domains in signal transduction proteins. *Cell* 1995, 80, 237–248.
23. Mayer, B.J.; Baltimore, D. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. *Mol. Cell. Biol.* 1994, 14, 2883–2894.
24. McWhirter, J.R.; Galasso, D.L.; Wang, J.Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. *Mol. Cell. Biol.* 1993, 13, 7587–7595.
25. Ma, G.; Lu, D.; Wu, Y.; Liu, J.; Arlinghaus, R.B. Bcr phosphorylated on tyrosine 177 binds Grb2. *Oncogene* 1997, 14, 2367–2372.
26. Steelman, L.S.; A Franklin, R.; Abrams, S.L.; Chappell, W.; Kempf, C.R.; Bäsecke, J.; Stivala, F.; Donia, M.; Fagone, P.; Nicoletti, F.; et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. *Leukemia* 2011, 25, 1080–1094.
27. Walker, S.R.; Frank, D.A. STAT Signaling in the Pathogenesis and Treatment of Cancer. In *Signaling Pathways in Cancer Pathogenesis and Therapy*; Springer: New York, NY, USA, 2012;

pp. 95–108.

28. Martelli, A.M.; Evangelisti, C.; Chappell, W.; Abrams, S.L.; Bäsecke, J.; Stivala, F.; Donia, M.; Fagone, P.; Nicoletti, F.; Libra, M.; et al. Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. *Leukemia* 2011, 25, 1064–1079.

29. Puil, L.; Liu, J.; Gish, G.; Mbamalu, G.; Bowtell, D.; Pelicci, P.; Arlinghaus, R.; Pawson, T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. *EMBO J.* 1994, 13, 764–773.

30. Bedi, A.; Zehnbauer, B.; Barber, J.; Sharkis, S.; Jones, R. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. *Blood* 1994, 83, 2038–2044.

31. Gordon, M.Y.; Dowding, C.R.; Riley, G.; Goldman, J.M.; Greaves, M.F. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. *Nat. Cell Biol.* 1987, 328, 342–344.

32. Clarkson, B.H.; Strife, A.; Wisniewski, D.; Lambek, C.; Liu, C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. *Leukemia* 2003, 17, 1211–1262.

33. Pendergast, A.M.; Quilliam, L.A.; Cripe, L.D.; Bassing, C.H.; Dai, Z.; Li, N.; Batzer, A.; Rabun, K.M.; Der, C.J.; Schlessinger, J.; et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. *Cell* 1993, 75, 175–185.

34. Minot, G.R.; Buckman, T.E.; Isaacs, R. Chronic myelogenous leukemia: Age incidence, duration, and benefit derived from irradiation. *J. Am. Med. Assoc.* 1924, 82, 1489–1494.

35. Rushing, D.; Goldman, A.; Gibbs, G.; Howe, R.; Kennedy, B.J. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. *Am. J. Clin. Oncol. Cancer Clin. Trials* 1982, 5, 307–314.

36. Tura, S.; Baccarani, M. α -interferon in the treatment of chronic myeloid leukemia. *Blood* 1995, 85, 2999–3000.

37. Lübking, A.; Dreimane, A.; Sandin, F.; Isaksson, C.; Märkevärn, B.; Brune, M.; Ljungman, P.; Lenhoff, S.; Stenke, L.; Höglund, M.; et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: Population-based data from the Swedish CML registry. *Bone Marrow Transplant.* 2019, 54, 1764–1774.

38. Gale, R.P.; Hehlmann, R.; Zhang, M.J.; Hasford, J.; Goldman, J.M.; Heimpel, H.; Hochhaus, A.; Klein, J.P.; Kolb, H.J.; McGlave, P.B.; et al. Survival with Bone Marrow Transplantation Versus Hydroxyurea or Interferon for Chronic Myelogenous Leukemia. *Blood* 1998, 91, 1810–1819.

39. Van Rhee, F.; Szydlo, R.; Hermans, J.; Devergie, A.; Frassoni, F.; Arcese, W.; De Witte, T.; Kolb, H.; Niederwiser, D.; Jacobsen, N.; et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic

Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997, 20, 553–560.

40. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Müller, M.; Druker, B.J.; Lydon, N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. *Cancer Res.* 1996, 56, 100–104.

41. Bhatia, R.; A Munthe, H.; Verfaillie, C. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β 1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. *Leukemia* 1998, 12, 1708–1717.

42. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug. *Nat. Rev. Drug Discov.* 2002, 1, 493–502.

43. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. *N. Engl. J. Med.* 2001, 344, 1031–1037.

44. Milojkovic, D.; Aupperley, J. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. *Clin. Cancer Res.* 2009, 15, 7519–7527.

45. Jabbour, E.; Kantarjian, H.; Cortes, J. Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm. *Clin. Lymphoma Myeloma Leuk.* 2015, 15, 323–334.

46. Mojica, F.J.M.; Montoliu, L. On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals. *Trends Microbiol.* 2016, 24, 811–820.

47. Wassef, M.; Luscan, A.; Battistella, A.; Le Corre, S.; Li, H.; Wallace, M.; Vidaud, M.; Margueron, R. Versatile and precise gene-targeting strategies for functional studies in mammalian cell lines. *Methods* 2017, 121–122, 45–54.

48. Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science* 2012, 337, 816–821.

49. Carroll, D. Genome engineering with zinc-finger nucleases. *Genetics* 2011, 188, 773–782.

Retrieved from <https://encyclopedia.pub/entry/history/show/33750>